Every story stays here. Filter by topic, search older headlines, and save favorites to your member record. Educational notes only — not medical advice.
Study (mathematical model checked against lab images, not a treatment trial). ScienceDaily carried the Mississippi State University account on 11 October 2026. Shantia Yarahmadian, Yasser Alzahrani, and Vaghawan Prasad Ojha report in the Bulletin of Mathematical Biology (2026; 88(9); doi 10.1007/s11538-026-01732-1). The model simulates how copper and zinc ions may change aggregation of amyloid-beta, a protein that can form plaques studied in Alzheimer's disease. It also explores two hypothetical ways of interfering with that clumping. The authors compared the simulations with atomic force microscopy of protein clusters. Yarahmadian said the equations matched patterns seen in those images and that mathematics does not replace laboratory or clinical research. The release does not report a patient group, a sex split, or an age band, and it does not show that blocking these metals treats Alzheimer's disease. Educational notes. This is not a test and not a supplement instruction.
Study (phase 2 meeting analysis of an experimental drug, plus separate animal work). ScienceDaily carried the European Association for the Study of Diabetes account on 11 October 2026 from the annual meeting in Milan. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals described CBL-514, an injection meant to make fat cells die rather than only empty them. In a subcutaneous-fat phase 2 result, 69.6 percent of people on CBL-514 had lost at least 150 mL of subcutaneous fat volume at eight weeks, and none on placebo reached that mark. A pooled look at MRI subsets from trials CBL-0204 and CBL-0205 included people with body mass index 22 to 30 who had injections in the lower abdomen every three weeks for up to 12 weeks, up to 600 mg (23 on the drug, 17 on placebo at the later scan). Average age across the groups ran from 36.4 to 42.4 years. Of the 23 on the drug, 17 were women and 6 were men. Starting visceral fat averaged 563.85 mL on the drug and 659.81 mL on placebo. Four weeks after the last injection, visceral fat was 12.01 percent below baseline on the drug and 5.68 percent above baseline on placebo. At the later scan it was still 10.45 percent below baseline on the drug and 11.76 percent above on placebo. Most side effects were mild or moderate pain, swelling, or redness at the injection site. No serious adverse events were reported in that account. Separate animal work, not the human MRI analysis, found less weight regain after tirzepatide was stopped when CBL-514 had been added. The release names Ozempic, Wegovy, Mounjaro, and Zepbound as the GLP-1 receptor agonist setting for that question and says the regain finding is not yet shown in people. Phase 3 recruitment was underway. Garvey said cosmetic flattening is not the health endpoint. Educational notes. CBL-514 is experimental. It is not a supplement, not a substitute for a prescribed medicine, and not something to start from a headline. Off-label or unapproved use is clinician-only and, here, still a trial question. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (mouse imaging, not a human treatment). ScienceDaily carried the University of British Columbia account on 11 October 2026. The university materials are dated July 2026. Babishaa Sauntharrajan, Neeru Gupta, Yeni H. Yücel, and colleagues, with the University of Toronto, report in Translational Vision Science & Technology (2026; 15(7):23; doi 10.1167/tvst.15.7.23). Using MRI, near-infrared fluorescence, and microscopy, they put tracer into a space at the back of the mouse eye. Fluid moved through small lymphatic vessels in the choroid, the layer under the retina, out into the tissues around the eye, and reached nearby lymph nodes within minutes. They call the route the posterior ocular lymphatic outflow, or POLO, pathway. Gupta said the retina makes constant waste and that this route may explain how some of it leaves. The release links glaucoma and age-related macular degeneration with fluid, waste, and inflammation at the back of the eye, and says age-related macular degeneration affects about 2.5 million Canadians. It does not show that the pathway works the same way in people, or that it can be boosted as a treatment. Sex and age of the mice are not given. A 2009 front-of-eye lymphatic route by Gupta and Yücel is cited as earlier work, not as this result. Educational notes. This is not an eye treatment.
Study (observational; not a trial). ScienceDaily carried the Tulane University account on 10 October 2026. Xuan Wang, Hao Ma, Yoriko Heianza, Zhaoxia Liang, Oscar H. Franco, and Lu Qi report in Nature Communications (2026; 17(1); doi 10.1038/s41467-026-74498-8). The cohort was 277,489 adults ages 40 to 69 who, at the start, did not have diabetes, heart disease, lung disease, dementia, cancer, depression, or anxiety. Using age 50 as the reference, women with both loneliness and social isolation had 2.4 fewer years free of physical disease and about 3.7 fewer years free of mental disorders than people with neither. Men with both had 1.7 fewer years free of physical disease and about 5.8 fewer years free of depression and anxiety. The release separates social isolation (few connections) from loneliness (dissatisfaction with those connections). Healthier diet, exercise, sleep, and not smoking reduced the loss tied to isolation; the same habits did not clearly reduce the loss tied to loneliness. Qi said the team plans other populations and trials, because this analysis does not show that loneliness causes the missing years. Educational notes. This is not medical advice.
Study (laboratory liver work; the release does not report a human exposure trial). ScienceDaily carried the Texas A&M account on 10 October 2026. The university materials are dated 3 August 2026. Woncheol Jung, Aditya D. Joshi, Tae Gyu Oh, and colleagues, with the University of Oklahoma, report in Science Advances (2026; 12(25); doi 10.1126/sciadv.aec8681). Polyethylene is described as about one-third of world plastic production and as used in food wrappers, containers, and cup linings. Joshi said few studies had looked at polyethylene and the liver. Exposure increased signs of fatty liver even without an unhealthy diet. Combined with a diet rich in fat, fructose, and cholesterol, the liver findings were more severe. Spatial transcriptomics, which keeps each cell's place in the tissue, mapped the damage. The release names PPAR-alpha, a protein that helps the liver handle fat, as activated, and ANXA2, a gene tied to tissue repair, as another contributor. Joshi said polyethylene had been treated as relatively inert. The team plans to look at scarring and at other plastics. The release does not give a human dose or a sex or age group. Educational notes. This is not a diagnosis of fatty liver and not a detox product claim.
Study (randomized trial; the journal year is earlier than the news date). ScienceDaily carried the University of Utah account on 10 October 2026. Scott D. Uhlrich and colleagues report in The Lancet Rheumatology (2025; 7(10):e708; doi 10.1016/S2665-9913(25)00151-1). The U.S. Department of Veterans Affairs is listed as the funder. People with mild to moderate osteoarthritis of the inner knee were scanned and walked on a force-sensing treadmill. Each person tried toe-in or toe-out of 5 or 10 degrees. People for whom no angle reduced inner-knee load were excluded. Sixty-eight participants were split into two groups of 34. One group trained a personal foot angle. The other walked with the same sessions but kept their usual angle. Both did six weekly treadmill sessions with a shin device that vibrated when the foot left the assigned angle, then were asked to practice at least 20 minutes a day. A year later, pain on a 0 to 10 scale fell by 2.5 points with the personal angle and 1.3 points with the sham. An exploratory count found a clinically meaningful pain drop in about 91 percent versus 66 percent. One MRI measure of inner-knee cartilage (T1rho) worsened more slowly in the trained group. A second MRI measure did not differ. Two people in the trained group and one in the sham group stopped because pain increased. No severe adverse events were reported. The release does not give the participants' ages or sex. Uhlrich said the same toe angle is wrong for some people and that this is not a home tweak to invent without a measurement. A separate University of Bath trial in Clinical Biomechanics (2026; 134:106776) of 50 people over six weeks found pain improved in every group, including the control, while only one feedback method cut a knee-load measure by 7.6 percent at one month. That trial did not track cartilage for a year. Educational notes. This is not a prescription to turn the toes in or out.
Study (laboratory and preclinical tests, not a human pain trial). ScienceDaily carried the New York University account on 10 October 2026. Mohamed Elsherif, Khalil B. Ramadi, and colleagues at NYU Abu Dhabi, with Cleveland Clinic Abu Dhabi, report in Science Advances (2026; 12(24); doi 10.1126/sciadv.aeg1437). The device is described as about the size of a small seed, injected through a needle, and placed near a nerve. It sends electrical pulses powered wirelessly from outside the body, with no implanted battery and no connecting wire. Ultrasound and CT are described as ways to check where it sits. The team said it delivered stimulation in lab conditions and activated nerves in a living animal. The release does not name the species, and it states that relief of chronic pain or a change in movement disorders has not been shown in patients. Ramadi said the aim is an option beside medicines and surgically implanted stimulators, not a replacement already proven in the clinic. Educational notes. This is not a treatment available to start, and not medical advice.
Study (six-month exercise comparison). ScienceDaily carried the University of the Sunshine Coast account on 9 October 2026. Grace Rose, Mia Schaumberg, and colleagues report in Maturitas (2025; 203:108763; doi 10.1016/j.maturitas.2025.108763). The news date is later than the journal year. 123 healthy adults from Greater Brisbane, average age 72 and average body mass index about 26, did three supervised 45-minute gym sessions a week for six months, assigned to high-intensity intervals, moderate intensity, or low intensity. Body composition was scanned at the start, at three months, and at six months. High and moderate training reduced fat mass more than low intensity. Moderate training also came with a small drop in lean mass. Interval training reduced fat without that lean-mass drop. High and moderate training improved fat carried around the middle, including visceral fat. The release says the changes were small and not clearly meaningful in the clinic once measurement uncertainty was counted. Scans measured lean tissue, not strength. The release does not split results by sex. A later home-interval paper and an HIV exercise trial are cited as separate studies, not as this trial. People who are inactive or who have a medical condition were pointed toward building up slowly and getting guidance before hard intervals. Educational notes. This is not a training prescription.
Study (brain recordings, not a treatment trial). ScienceDaily carried the University of Helsinki account on 9 October 2026. Wenya Liu, Satu Palva, J. Matias Palva, and colleagues report in Nature Mental Health (2026; 4(10):1534; doi 10.1038/s44220-026-00723-4), with Aalto University and Helsinki and Uusimaa Hospital District. Researchers recorded magnetoencephalography in 263 people with major depressive disorder and 75 people without depression. Functional connectivity, how closely regions fired together, fell into five profiles. One had fairly strong connectivity and more severe depression, anxiety, rumination, and trouble with daily function. One had weaker connectivity and milder symptoms. One had weak connectivity across a large part of the brain and more prominent trauma symptoms. One mixed strong and weak connections and had more severe depression, more substance use, and lower well-being. One had the strongest connectivity, with substance use prominent and trauma symptoms less so. All five differed from the comparison group in which regions and which frequencies were involved. Palva said stronger connectivity is not automatically better, and that the scans are not yet a way to pick a treatment. The release does not give sex or age. Educational notes. This is not a depression test.
Meeting presentation (the release does not cite a journal paper). The Menopause Society posted this on 9 October 2026. The dateline reads 20 October 2026, and the work is scheduled for the society's annual meeting in San Diego on 20-24 October 2026. Zailing Xing and colleagues used the ARIC study: more than 4,700 postmenopausal women ages 45 to 64, mean follow-up 21.4 years, 1,570 cardiovascular events. Premature menopause means menopause before age 40. Compared with menopause at or after 45, premature menopause was associated with higher risk of cardiovascular disease and of coronary heart disease, and not with stroke or heart failure. Menopause at ages 40 to 44 was not associated with those higher risks in this release. Insulin was 9.3 percent higher after premature menopause. Fasting glucose did not differ. The authors say insulin resistance may be one path between early menopause and later heart disease. Stephanie Faubion, medical director of The Menopause Society, said the reasons are not fully understood and that this is not itself a treatment test. The people followed were 45 to 64, so this row is not tagged as a current under-40 audience even though the menopause happened before 40. Educational notes. This is not medical advice.
Review (not a new clinical trial). ScienceDaily carried the Higher Education Press account on 9 October 2026. Yi Ru, Yunxi Cai, and colleagues report in MedScience (2025; 19(6):950; doi 10.1007/s11684-025-1190-y). The news date is later than the journal year. The review covers monocytes, macrophages, dendritic cells, neutrophils, mast cells, B cells, T cells, and natural killer cells across the stages of wound healing. It says more than 131 million people have chronic diabetic ulcers, with about $755 billion a year in costs, and with amputation and death among the risks. The authors' reading is that macrophages in diabetic wounds often stay in a pro-inflammatory state instead of shifting toward repair. They also describe poorly controlled neutrophil traps, different mast-cell behavior, weaker debris cleanup by dendritic cells, and fewer or less active regulatory T cells. SLC7A11 is named as one transporter that may be less active in diabetes. The piece discusses experimental ideas, including drugs that push macrophages toward repair, stem-cell vesicles, dressings, and an IL-15 superagonist, and it says timing may matter because each healing stage has a different immune mix. Some of those ideas are described as having early randomized data and some as still laboratory work. The release does not give one new patient sample, sex split, or age band. Educational notes. This is not wound-care advice and not a product claim.
Study (meta-analysis of randomized trials). ScienceDaily carried the University of Surrey account on 8 October 2026. Emily I. G. Brown and colleagues report in Nutrition Reviews (2025; doi 10.1093/nutrit/nuaf166), with the John Innes Centre and the Quadram Institute. The news date is later than that paper. The review covered 20 trials, with 11 in the main meta-analysis. People taking vitamin D2 (ergocalciferol) had lower 25-hydroxyvitamin D3 than people not given D2, by roughly 9 to 18 nanomoles per liter depending on the analysis. D2 still raises 25-hydroxyvitamin D2 and can add to total vitamin D. The release says this is not evidence that D2 removes vitamin D from the body. A separate 2026 review of 26 trials (Nutrition Reviews 2026; 84(3):571; doi 10.1093/nutrit/nuaf102) found D2 lowered parathyroid hormone and slightly raised blood calcium. An earlier gene-activity study from the same university is described as suggesting D3, not D2, lined up with type I interferon signaling. That is not proof that D3 prevents infection. The release does not give one age band or a sex split. Researchers said it is still unknown whether the D3 drop changes long-term health. This is not a reason to start, stop, or switch a supplement from a headline. Educational notes. This is not medical advice.
VitaLonga is an educational longevity resource, not a pharmacy, clinic, or doctor. Content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease (DSHEA). Supplements can interact with medications and are not appropriate in every pregnancy or health condition. Consult a licensed clinician, especially if you take medications, are pregnant or nursing, or have a diagnosed condition.
